Skip to main content
Top
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data

Authors: Olga Dmitrieva, Simon de Lusignan, Iain C Macdougall, Hugh Gallagher, Charles Tomson, Kevin Harris, Terry Desombre, David Goldsmith

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Anaemia is a known risk factor for cardiovascular disease and treating anaemia in chronic kidney disease (CKD) may improve outcomes. However, little is known about the scope to improve primary care management of anaemia in CKD.

Methods

An observational study (N = 1,099,292) with a nationally representative sample using anonymised routine primary care data from 127 Quality Improvement in CKD trial practices (ISRCTN5631023731). We explored variables associated with anaemia in CKD: eGFR, haemoglobin (Hb), mean corpuscular volume (MCV), iron status, cardiovascular comorbidities, and use of therapy which associated with gastrointestinal bleeding, oral iron and deprivation score. We developed a linear regression model to identify variables amenable to improved primary care management.

Results

The prevalence of Stage 3–5 CKD was 6.76%. Hb was lower in CKD (13.2 g/dl) than without (13.7 g/dl). 22.2% of people with CKD had World Health Organization defined anaemia; 8.6% had Hb ≤ 11 g/dl; 3% Hb ≤ 10 g/dl; and 1% Hb ≤ 9 g/dl. Normocytic anaemia was present in 80.5% with Hb ≤ 11; 72.7% with Hb ≤ 10 g/dl; and 67.6% with Hb ≤ 9 g/dl; microcytic anaemia in 13.4% with Hb ≤ 11 g/dl; 20.8% with Hb ≤ 10 g/dl; and 24.9% where Hb ≤ 9 g/dl. 82.7% of people with microcytic and 58.8% with normocytic anaemia (Hb ≤ 11 g/dl) had a low ferritin (<100ug/mL). Hypertension (67.2% vs. 54%) and diabetes (30.7% vs. 15.4%) were more prevalent in CKD and anaemia; 61% had been prescribed aspirin; 73% non-steroidal anti-inflammatory drugs (NSAIDs); 14.1% warfarin 12.4% clopidogrel; and 53.1% aspirin and NSAID. 56.3% of people with CKD and anaemia had been prescribed oral iron. The main limitations of the study are that routine data are inevitably incomplete and definitions of anaemia have not been standardised.

Conclusions

Medication review is needed in people with CKD and anaemia prior to considering erythropoietin or parenteral iron. Iron stores may be depleted in over >60% of people with normocytic anaemia. Prescribing oral iron has not corrected anaemia.
Appendix
Available only for authorised users
Literature
1.
go back to reference Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J: Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002, 39 (11): 1780-1786. 10.1016/S0735-1097(02)01854-5.CrossRefPubMed Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J: Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002, 39 (11): 1780-1786. 10.1016/S0735-1097(02)01854-5.CrossRefPubMed
2.
go back to reference Mozaffarian D, Nye R, Levy WC: Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003, 41 (11): 1933-1939. 10.1016/S0735-1097(03)00425-X.CrossRefPubMed Mozaffarian D, Nye R, Levy WC: Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003, 41 (11): 1933-1939. 10.1016/S0735-1097(03)00425-X.CrossRefPubMed
3.
go back to reference Eckardt KU: Managing a fateful alliance: anaemia and cardiovascular outcomes. Nephrol Dial Transplant. 2005, 20 (Suppl 6): vi16-20.PubMed Eckardt KU: Managing a fateful alliance: anaemia and cardiovascular outcomes. Nephrol Dial Transplant. 2005, 20 (Suppl 6): vi16-20.PubMed
4.
go back to reference Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med. 2002, 162 (12): 1401-1408. 10.1001/archinte.162.12.1401.CrossRefPubMed Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med. 2002, 162 (12): 1401-1408. 10.1001/archinte.162.12.1401.CrossRefPubMed
5.
go back to reference Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003, 41 (1): 1-12.CrossRefPubMed Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003, 41 (1): 1-12.CrossRefPubMed
6.
go back to reference Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP: PRE-dialysis survey on anaemia management. Nephrol Dial Transplant. 2003, 18 (1): 89-100. 10.1093/ndt/18.1.89.CrossRefPubMed Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP: PRE-dialysis survey on anaemia management. Nephrol Dial Transplant. 2003, 18 (1): 89-100. 10.1093/ndt/18.1.89.CrossRefPubMed
7.
go back to reference John R, Webb M, Young A, Stevens PE: Unreferred chronic kidney disease: a longitudinal study. Am J Kidney Dis. 2004, 43 (5): 825-835. 10.1053/j.ajkd.2003.12.046.CrossRefPubMed John R, Webb M, Young A, Stevens PE: Unreferred chronic kidney disease: a longitudinal study. Am J Kidney Dis. 2004, 43 (5): 825-835. 10.1053/j.ajkd.2003.12.046.CrossRefPubMed
8.
go back to reference Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ. 1990, 300 (6724): 573-578.CrossRef Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ. 1990, 300 (6724): 573-578.CrossRef
9.
go back to reference Finkelstein FO, Story K, Firanek C, Mendelssohn D, Barre P, Takano T, Soroka S, Mujais S: Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009, 4 (1): 33-38. 10.2215/CJN.00630208.CrossRefPubMedPubMedCentral Finkelstein FO, Story K, Firanek C, Mendelssohn D, Barre P, Takano T, Soroka S, Mujais S: Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009, 4 (1): 33-38. 10.2215/CJN.00630208.CrossRefPubMedPubMedCentral
10.
go back to reference Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995, 47 (3): 884-890. 10.1038/ki.1995.132.CrossRefPubMed Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995, 47 (3): 884-890. 10.1038/ki.1995.132.CrossRefPubMed
11.
go back to reference Walker AM, Schneider G, Yeaw J, Nordstrom B, Robbins S, Pettitt D: Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol. 2006, 17 (8): 2293-2298. 10.1681/ASN.2005020183.CrossRefPubMed Walker AM, Schneider G, Yeaw J, Nordstrom B, Robbins S, Pettitt D: Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol. 2006, 17 (8): 2293-2298. 10.1681/ASN.2005020183.CrossRefPubMed
12.
go back to reference Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, et al: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999, 34 (1): 125-134. 10.1016/S0272-6386(99)70118-6.CrossRefPubMed Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, et al: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999, 34 (1): 125-134. 10.1016/S0272-6386(99)70118-6.CrossRefPubMed
13.
go back to reference El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, Bakris GL, Keane WF, Flack JM: Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005, 67 (4): 1483-1488. 10.1111/j.1523-1755.2005.00226.x.CrossRefPubMed El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, Bakris GL, Keane WF, Flack JM: Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005, 67 (4): 1483-1488. 10.1111/j.1523-1755.2005.00226.x.CrossRefPubMed
14.
go back to reference Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, Herzog CA: Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2005, 45 (3): 391-399. 10.1016/j.jacc.2004.10.038.CrossRefPubMed Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, Herzog CA: Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2005, 45 (3): 391-399. 10.1016/j.jacc.2004.10.038.CrossRefPubMed
15.
go back to reference de Lusignan S: An educational intervention, involving feedback of routinely collected computer data, to improve cardiovascular disease management in UK primary care. Methods Inf Med. 2007, 46 (1): 57-62.PubMed de Lusignan S: An educational intervention, involving feedback of routinely collected computer data, to improve cardiovascular disease management in UK primary care. Methods Inf Med. 2007, 46 (1): 57-62.PubMed
16.
go back to reference Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM: Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. Ann Pharmacother. 2007, 41 (11): 1761-1769. 10.1345/aph.1K194.CrossRefPubMed Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM: Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. Ann Pharmacother. 2007, 41 (11): 1761-1769. 10.1345/aph.1K194.CrossRefPubMed
17.
go back to reference Anderson J, Glynn LG, Newell J, Iglesias AA, Reddan D, Murphy AW: The impact of renal insufficiency and anaemia on survival in patients with cardiovascular disease: a cohort study. BMC Cardiovasc Disord. 2009, 9: 51-10.1186/1471-2261-9-51.CrossRefPubMedPubMedCentral Anderson J, Glynn LG, Newell J, Iglesias AA, Reddan D, Murphy AW: The impact of renal insufficiency and anaemia on survival in patients with cardiovascular disease: a cohort study. BMC Cardiovasc Disord. 2009, 9: 51-10.1186/1471-2261-9-51.CrossRefPubMedPubMedCentral
18.
go back to reference Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P: Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol. 2009, 4 (4): 755-762. 10.2215/CJN.02730608.CrossRefPubMedPubMedCentral Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P: Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol. 2009, 4 (4): 755-762. 10.2215/CJN.02730608.CrossRefPubMedPubMedCentral
19.
go back to reference Goldberg N, Lundin AP, Delano B, Friedman EA, Stein RA: Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J. 1992, 124 (2): 424-427. 10.1016/0002-8703(92)90608-X.CrossRefPubMed Goldberg N, Lundin AP, Delano B, Friedman EA, Stein RA: Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J. 1992, 124 (2): 424-427. 10.1016/0002-8703(92)90608-X.CrossRefPubMed
20.
go back to reference Wish JB, Nassar GM, Schulman K, del Aguila M, Provenzano R: Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease. Clin Nephrol. 2008, 69 (4): 251-259.CrossRefPubMed Wish JB, Nassar GM, Schulman K, del Aguila M, Provenzano R: Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease. Clin Nephrol. 2008, 69 (4): 251-259.CrossRefPubMed
21.
go back to reference Foley RN, Curtis BM, Parfrey PS: Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clin J Am Soc Nephrol. 2008, 3 (6): 1669-1675. 10.2215/CJN.02100508.CrossRefPubMedPubMedCentral Foley RN, Curtis BM, Parfrey PS: Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clin J Am Soc Nephrol. 2008, 3 (6): 1669-1675. 10.2215/CJN.02100508.CrossRefPubMedPubMedCentral
22.
go back to reference Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997, 77 (2): 176-185. 10.1159/000190270.CrossRefPubMed Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997, 77 (2): 176-185. 10.1159/000190270.CrossRefPubMed
23.
go back to reference Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, et al: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000, 35 (7): 1737-1744. 10.1016/S0735-1097(00)00613-6.CrossRefPubMed Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, et al: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000, 35 (7): 1737-1744. 10.1016/S0735-1097(00)00613-6.CrossRefPubMed
26.
go back to reference Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003, 107 (2): 294-299. 10.1161/01.CIR.0000044914.42696.6A.CrossRefPubMed Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003, 107 (2): 294-299. 10.1161/01.CIR.0000044914.42696.6A.CrossRefPubMed
27.
go back to reference Tehrani F, Dhesi P, Daneshvar D, Phan A, Rafique A, Siegel RJ, Cercek B: Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis. Cardiovasc Drugs Ther. 2009, 23 (6): 511-518. 10.1007/s10557-009-6203-6.CrossRefPubMed Tehrani F, Dhesi P, Daneshvar D, Phan A, Rafique A, Siegel RJ, Cercek B: Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis. Cardiovasc Drugs Ther. 2009, 23 (6): 511-518. 10.1007/s10557-009-6203-6.CrossRefPubMed
28.
go back to reference Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, et al: Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008, 117 (4): 526-535. 10.1161/CIRCULATIONAHA.107.698514.CrossRefPubMed Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, et al: Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008, 117 (4): 526-535. 10.1161/CIRCULATIONAHA.107.698514.CrossRefPubMed
29.
go back to reference Desai A, Lewis E, Solomon S, McMurray JJ, Pfeffer M: Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail. 2010, 12 (9): 936-942. 10.1093/eurjhf/hfq094.CrossRefPubMed Desai A, Lewis E, Solomon S, McMurray JJ, Pfeffer M: Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail. 2010, 12 (9): 936-942. 10.1093/eurjhf/hfq094.CrossRefPubMed
30.
go back to reference Singh AK: The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?. Am J Kidney Dis. 2008, 52 (6 Suppl): S5-13.CrossRefPubMed Singh AK: The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?. Am J Kidney Dis. 2008, 52 (6 Suppl): S5-13.CrossRefPubMed
32.
go back to reference de Lusignan S, Gallagher H, Chan T, Thomas N, van Vlymen J, Nation M, Jain N, Tahir A, du Bois E, Crinson I, et al: The QICKD study protocol: a cluster randomised trial to compare quality improvement interventions to lower systolic BP in chronic kidney disease (CKD) in primary care. Implement Sci. 2009, 4: 39-10.1186/1748-5908-4-39.CrossRefPubMedPubMedCentral de Lusignan S, Gallagher H, Chan T, Thomas N, van Vlymen J, Nation M, Jain N, Tahir A, du Bois E, Crinson I, et al: The QICKD study protocol: a cluster randomised trial to compare quality improvement interventions to lower systolic BP in chronic kidney disease (CKD) in primary care. Implement Sci. 2009, 4: 39-10.1186/1748-5908-4-39.CrossRefPubMedPubMedCentral
33.
go back to reference de Lusignan S, Gallagher H, Jones S, Chan T, van Vlymen J, Tahir A, Thomas N, Jain N, Dmitrieva O, Rafi I, et al: Using audit-based education to lower systolic blood pressure in chronic kidney disease (CKD): results of the quality improvement in CKD (QICKD) trial [ISRCTN: 56023731]. Accepted for Publication Kidney International, 13th January 2013, Ref: KI-06-12-0863.R3 de Lusignan S, Gallagher H, Jones S, Chan T, van Vlymen J, Tahir A, Thomas N, Jain N, Dmitrieva O, Rafi I, et al: Using audit-based education to lower systolic blood pressure in chronic kidney disease (CKD): results of the quality improvement in CKD (QICKD) trial [ISRCTN: 56023731]. Accepted for Publication Kidney International, 13th January 2013, Ref: KI-06-12-0863.R3
34.
go back to reference van Vlymen J, de Lusignan S, Hague N, Chan T, Dzregah B: Ensuring the quality of aggregated general practice data: lessons from the primary care data Quality Programme (PCDQ). Stud Health Technol Inform. 2005, 116: 1010-1015.PubMed van Vlymen J, de Lusignan S, Hague N, Chan T, Dzregah B: Ensuring the quality of aggregated general practice data: lessons from the primary care data Quality Programme (PCDQ). Stud Health Technol Inform. 2005, 116: 1010-1015.PubMed
35.
go back to reference van Vlymen J, de Lusignan S: A system of metadata to control the process of query, aggregating, cleaning and analysing large datasets of primary care data. Inform Prim Care. 2005, 13 (4): 281-291.PubMed van Vlymen J, de Lusignan S: A system of metadata to control the process of query, aggregating, cleaning and analysing large datasets of primary care data. Inform Prim Care. 2005, 13 (4): 281-291.PubMed
37.
go back to reference de Lusignan S, Tomson C, Harris K, van Vlymen J, Gallagher H: Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease. Nephron Clin Pract. 2011, 117 (3): c213-224. 10.1159/000320341.CrossRefPubMed de Lusignan S, Tomson C, Harris K, van Vlymen J, Gallagher H: Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease. Nephron Clin Pract. 2011, 117 (3): c213-224. 10.1159/000320341.CrossRefPubMed
39.
go back to reference de Lusignan S, Tomson C, Harris K, van Vlymen J, Gallagher H: Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease. Nephron Clin Pract. 2010, 117 (3): c213-c224.CrossRefPubMed de Lusignan S, Tomson C, Harris K, van Vlymen J, Gallagher H: Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease. Nephron Clin Pract. 2010, 117 (3): c213-c224.CrossRefPubMed
40.
go back to reference Bessman JD, Johnson RK: Erythrocyte volume distribution in normal and abnormal subjects. Blood. 1975, 46 (3): 369-379.PubMed Bessman JD, Johnson RK: Erythrocyte volume distribution in normal and abnormal subjects. Blood. 1975, 46 (3): 369-379.PubMed
41.
go back to reference Agarwal AK: Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. J Am Med Dir Assoc. 2006, 7 (9 Suppl): S7-S12. quiz S17-21CrossRefPubMed Agarwal AK: Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. J Am Med Dir Assoc. 2006, 7 (9 Suppl): S7-S12. quiz S17-21CrossRefPubMed
42.
go back to reference Grabe DW: Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease. Am J Health Syst Pharm. 2007, 64 (13 Suppl 8): S8-14. quiz S23-15CrossRefPubMed Grabe DW: Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease. Am J Health Syst Pharm. 2007, 64 (13 Suppl 8): S8-14. quiz S23-15CrossRefPubMed
43.
go back to reference Stancu S, Stanciu A, Zugravu A, Barsan L, Dumitru D, Lipan M, Mircescu G: Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis. 2010, 55 (4): 639-647. 10.1053/j.ajkd.2009.10.043.CrossRefPubMed Stancu S, Stanciu A, Zugravu A, Barsan L, Dumitru D, Lipan M, Mircescu G: Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis. 2010, 55 (4): 639-647. 10.1053/j.ajkd.2009.10.043.CrossRefPubMed
44.
go back to reference Smellie WS, Forth J, Bareford D, Twomey P, Galloway MJ, Logan EC, Smart SR, Reynolds TM, Waine C: Best practice in primary care pathology: review 3. J Clin Pathol. 2006, 59 (8): 781-789. 10.1136/jcp.200X.033944.CrossRefPubMedPubMedCentral Smellie WS, Forth J, Bareford D, Twomey P, Galloway MJ, Logan EC, Smart SR, Reynolds TM, Waine C: Best practice in primary care pathology: review 3. J Clin Pathol. 2006, 59 (8): 781-789. 10.1136/jcp.200X.033944.CrossRefPubMedPubMedCentral
45.
go back to reference Goddard AF, James MW, McIntyre AS, Scott BB: Guidelines for the management of iron deficiency anaemia. Gut. 2011 Goddard AF, James MW, McIntyre AS, Scott BB: Guidelines for the management of iron deficiency anaemia. Gut. 2011
46.
go back to reference Bowling CB, Inker LA, Gutierrez OM, Allman RM, Warnock DG, McClellan W, Muntner P: Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications. Clin J Am Soc Nephrol. 2011, 6 (12): 2822-2828. 10.2215/CJN.06770711.CrossRefPubMedPubMedCentral Bowling CB, Inker LA, Gutierrez OM, Allman RM, Warnock DG, McClellan W, Muntner P: Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications. Clin J Am Soc Nephrol. 2011, 6 (12): 2822-2828. 10.2215/CJN.06770711.CrossRefPubMedPubMedCentral
47.
go back to reference Michalakidis G, Kumarapeli P, Ring A, van Vlymen J, Krause P, de Lusignan S: A system for solution-orientated reporting of errors associated with the extraction of routinely collected clinical data for research and quality improvement. Stud Health Technol Inform. 2010, 160 (Pt 1): 724-728.PubMed Michalakidis G, Kumarapeli P, Ring A, van Vlymen J, Krause P, de Lusignan S: A system for solution-orientated reporting of errors associated with the extraction of routinely collected clinical data for research and quality improvement. Stud Health Technol Inform. 2010, 160 (Pt 1): 724-728.PubMed
48.
go back to reference de Lusignan S, Chan T, Stevens P, O'Donoghue D, Hague N, Dzregah B, Van Vlymen J, Walker M, Hilton S: Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005, 22 (3): 234-241. 10.1093/fampra/cmi026.CrossRefPubMed de Lusignan S, Chan T, Stevens P, O'Donoghue D, Hague N, Dzregah B, Van Vlymen J, Walker M, Hilton S: Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005, 22 (3): 234-241. 10.1093/fampra/cmi026.CrossRefPubMed
50.
go back to reference Kidney Disease Improving Global Outcomes (KDIGO): Clinical Practice Guideline for anaemia in chronic disease. Kidney International. 2012, 2: 282-10.1038/kisup.2012.40.CrossRef Kidney Disease Improving Global Outcomes (KDIGO): Clinical Practice Guideline for anaemia in chronic disease. Kidney International. 2012, 2: 282-10.1038/kisup.2012.40.CrossRef
51.
go back to reference McFarlane SI, Chen SC, Whaley-Connell AT, Sowers JR, Vassalotti JA, Salifu MO, Li S, Wang C, Bakris G, McCullough PA, Kidney Early Evaluation Program Investigators, et al: Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis. 2008, 51 (4 Suppl 2): S46-55. 10.1053/j.ajkd.2007.12.019.CrossRefPubMed McFarlane SI, Chen SC, Whaley-Connell AT, Sowers JR, Vassalotti JA, Salifu MO, Li S, Wang C, Bakris G, McCullough PA, Kidney Early Evaluation Program Investigators, et al: Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis. 2008, 51 (4 Suppl 2): S46-55. 10.1053/j.ajkd.2007.12.019.CrossRefPubMed
52.
go back to reference Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008, 52 (5): 897-906. 10.1053/j.ajkd.2008.05.033.CrossRefPubMed Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008, 52 (5): 897-906. 10.1053/j.ajkd.2008.05.033.CrossRefPubMed
53.
go back to reference Clase CM, Kiberd BA, Garg AX: Relationship between glomerular filtration rate and the prevalence of metabolic abnormalities: results from the Third National Health and Nutrition Examination Survey (NHANES III). Nephron Clin Pract. 2007, 105 (4): c178-184. 10.1159/000100489.CrossRefPubMed Clase CM, Kiberd BA, Garg AX: Relationship between glomerular filtration rate and the prevalence of metabolic abnormalities: results from the Third National Health and Nutrition Examination Survey (NHANES III). Nephron Clin Pract. 2007, 105 (4): c178-184. 10.1159/000100489.CrossRefPubMed
54.
go back to reference Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B: High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant. 1998, 13 (5): 1206-1210. 10.1093/ndt/13.5.1206.CrossRefPubMed Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B: High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant. 1998, 13 (5): 1206-1210. 10.1093/ndt/13.5.1206.CrossRefPubMed
55.
go back to reference de Lusignan S, van Weel C: The use of routinely collected computer data for research in primary care: opportunities and challenges. Fam Pract. 2006, 23 (2): 253-263.CrossRefPubMed de Lusignan S, van Weel C: The use of routinely collected computer data for research in primary care: opportunities and challenges. Fam Pract. 2006, 23 (2): 253-263.CrossRefPubMed
56.
go back to reference CPR 1.1. Identifying patients and initiating evaluation II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006, 47 (5 Suppl 3): S16-85. CPR 1.1. Identifying patients and initiating evaluation II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006, 47 (5 Suppl 3): S16-85.
59.
go back to reference Wish JB: Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006, 1 (Suppl 1): S4-8.CrossRefPubMed Wish JB: Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006, 1 (Suppl 1): S4-8.CrossRefPubMed
Metadata
Title
Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data
Authors
Olga Dmitrieva
Simon de Lusignan
Iain C Macdougall
Hugh Gallagher
Charles Tomson
Kevin Harris
Terry Desombre
David Goldsmith
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-24

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.